Disease burden and risk factors of pancreatic cancer in China in 1990 and 2019
-
摘要:
目的 分析1990年和2019年中国胰腺癌发病、死亡和疾病负担情况。 方法 利用2019年全球疾病负担数据库，分析总人群、不同年龄组间1990年和2019年我国胰腺癌发病、死亡、伤残调整寿命年(DALY)、过早死亡损失寿命年(YLL)和伤残损失寿命年(YLD)，并对胰腺癌进行危险因素归因分析。 结果 2019年中国胰腺癌发病人数为11.49万，发病率为8.08/10万，较1990年分别增长了330.34%和257.52%。2019年死亡人数为11.74万，死亡率为8.25/10万，较1990年分别上升了333.21%和260.26%。2019年中国胰腺癌DALY、YLD和YLL分别为280.52万人年、2.39万人年和278.13万人年，较1990年分别上升了274.33%、319.30%和273.98%。2019年胰腺癌发病率、死亡率和DALY率均随年龄增长而升高，发病率、死亡率和DALY率最高的年龄组均为＞70岁年龄组，分别为44.75/10万、50.09/10万和742.81/10万。中国胰腺癌归因于吸烟导致的死亡人数、DALY和YLL分别为26 552人年、612 359人年和607 033人年。 结论 我国胰腺癌的疾病负担在1990—2019年间有较大增长，应采取积极的预防措施以减轻胰腺癌的疾病负担。 Abstract:Objective To analyse the incidence, mortality and disease burden of pancreatic cancer in China in 1990 and 2019. Methods The global disease burden database in 2019 was used to analyse the incidence, mortality, disability adjusted life years (DALY), premature death loss years (YLL) and disability life years (YLD) of pancreatic cancer in the total population and age groups in 1990 and 2019. Risk factors attributable to pancreatic cancer were also analysed. Results The incidence of pancreatic cancer in China was 114 900 in 2019, and the incidence rate was 8.08/105, representing an increase of 330.34% and 257.52% compared with 1990. In 2019, the number of deaths was 117 400, and the mortality rate was 8.25/105, indicating an increase of 333.21% and 260.26% compared with 1990. In 2019, the DALY, YLD and YLL of pancreatic cancer in China were 2 805 200, 23 900 and 2 781 300, by contrast, form 1990, such values increased by 274.33%, 319.30% and 273.98%, respectively. In 2019, the incidence rate, mortality rate and DALY rate of pancreatic cancer increased with age. The highest incidence rate (44.75/105), mortality rate (50.09/105) and DALY rate (742.81/105) were all observed in the >70 age group. The mortality rate, DALY and YLL attributed to smoking in Chinese patients with pancreatic cancer was 26 552, 612 359 and 607 033, respectively. Conclusion The burden of pancreatic cancer in China has increased considerably from 1990 to 2019. Therefore, positive preventive measures should be taken to reduce the burden of pancreatic cancer. -
Key words:
- Pancreatic cancer /
- Disease burden /
- Smoking /
- Disability adjusted life years
-
图 1 1990—2019年中国与部分国家胰腺癌死亡率分析
Figure 1. Pancreatic cancer mortality in China and some countries from 1990 to 2019
图 2 1990—2019年中国与部分国家胰腺癌DALY率分析
Figure 2. DALY rate of pancreatic cancer in China and some countries from 1990 to 2019
表 1 1990年和2019年胰腺癌发病和死亡情况
Table 1. Incidence and death of pancreatic cancer, 1990 and 2019
性别 发病数 发病率 标化发病率 1990年(万人) 2019年(万人) 变化率(%) 1990年(1/10万) 2019年(1/10万) 变化率(%) 1990年(1/10万) 2019年(1/10万) 变化率(%) 男性 1.58 6.96 340.51 2.59 9.61 271.04 3.89 7.43 91.00 女性 1.09 4.53 315.60 1.91 6.50 240.31 2.55 4.36 70.98 合计 2.67 11.49 330.34 2.26 8.08 257.52 3.17 5.78 82.33 性别 死亡数 死亡率 标化死亡率 1990年(万人) 2019年(万人) 变化率(%) 1990年(1/10万) 2019年(1/10万) 变化率(%) 1990年(1/10万) 2019年(1/10万) 变化率(%) 男性 1.59 7.02 341.51 2.60 9.69 272.69 4.12 7.69 86.65 女性 1.12 4.72 321.43 1.96 6.76 244.90 2.70 4.58 69.63 合计 2.71 11.74 333.21 2.29 8.25 260.26 3.34 5.99 79.34 
下载: 导出CSV
表 2 1990年和2019年胰腺癌疾病负担情况
Table 2. Disease burden of pancreatic cancer, 1990 and 2019
性别 DALY DALY率 YLD 1990年(万人年) 2019年(万人年) 变化率(%) 1990年(1/10万) 2019年(1/10万) 变化率(%) 1990年(万人年) 2019年(万人年) 变化率(%) 男性 45.55 176.05 286.50 74.66 242.89 225.33 0.34 1.44 323.53 女性 29.38 104.47 255.58 51.24 149.77 192.29 0.23 0.95 313.04 合计 74.94 280.52 274.33 63.31 197.22 211.51 0.57 2.39 319.30 性别 YLD率 YLL YLL率 1990年(1/10万) 2019年(1/10万) 变化率(%) 1990年(万人年) 2019年(万人年) 变化率(%) 1990年(1/10万) 2019年(1/10万) 变化率(%) 男性 0.56 1.99 255.36 45.21 174.61 286.22 74.10 240.90 225.10 女性 0.41 1.36 231.71 29.15 103.52 255.13 50.83 148.41 191.97 合计 0.48 1.68 250.00 74.37 278.13 273.98 62.83 195.54 211.22
下载: 导出CSV
表 3 1990年和2019年不同年龄组胰腺癌发病、死亡以及负担情况
Table 3. Incidence, death, and burden of pancreatic cancer by age group, 1990 and 2019
年龄(岁) 年份 发病率(1/10万) 死亡率(1/10万) DALY率(1/10万) 男性 女性 合计 男性 女性 合计 男性 女性 合计 15~49 1990年 0.80 0.45 0.63 0.72 0.40 0.56 35.19 19.48 27.60 2019年 2.19 0.83 1.53 1.96 0.73 1.36 91.71 33.82 63.51 变化率(%) 173.75 84.44 142.86 172.22 82.50 142.86 160.61 73.61 130.11 50~69 1990年 11.29 7.72 9.57 10.95 7.51 9.29 325.36 219.70 274.42 2019年 18.89 11.28 15.09 18.15 10.85 14.50 528.30 309.57 418.97 变化率(%) 67.32 46.11 57.68 65.75 44.47 56.08 62.37 40.91 52.67 ＞70 1990年 24.57 17.31 20.44 28.13 20.12 23.57 450.65 311.64 371.62 2019年 54.22 36.81 44.75 59.88 41.88 50.09 907.52 604.70 742.81 变化率(%) 120.68 112.65 118.93 112.87 108.15 112.52 101.38 94.04 99.88
下载: 导出CSV
表 4 1990年和2019年胰腺癌归因于3种危险因素的疾病负担
Table 4. Disease burden of pancreatic cancer attributed to the of three risk factors in 1990 and 2019
项目 死亡数 DALY YLL 1990年(人) 2019年(人) 变化率(%) 1990年(人) 2019年(人) 变化率(%) 1990年(人) 2019年(人) 变化率(%) 吸烟 5 529 26 552 380.23 142 185 612 359 330.68 141 037 607 033 330.41 代谢危险因素 1 952 11 992 514.34 48 675 275 175 465.33 48 274 272 759 465.02 高空腹血糖 1 523 8 045 428.23 36 617 175 495 379.27 36 309 173 904 378.96
下载: 导出CSV
-
[1] SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.21660 [2] MAISONNEUVE P. Epidemiology and burden of pancreatic cancer[J]. Presse Med, 2019, 48(3 Pt 2): e113-e123. http://www.onacademic.com/detail/journal_1000042279459099_c05f.html [3] 杨军, 李贺, 郑荣寿, 等. 2014年中国胰腺癌发病与死亡分析[J]. 中国肿瘤, 2018, 27(6): 420-425. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHLU201806005.htmYANG J, LI H, ZHENG R S, et al. Incidence and mortality of pancreatic cancer in China, 2014[J]. China Cancer, 2018, 27(6): 420-425. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHLU201806005.htm [4] GBD 2017 Pancreatic Cancer Collaborators. The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990—2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet Gastroenterol Hepatol, 2019, 4(12): 934-947. doi: 10.1016/S2468-1253(19)30347-4 [5] KLEIN A P. Pancreatic cancer: a growing burden[J]. Lancet Gastroenterol Hepatol, 2019, 4(12): 895-896. doi: 10.1016/S2468-1253(19)30323-1 [6] 王亮亮, 丁高恒, 陈莉莉, 等. 2009—2015年甘肃省肿瘤登记地区胰腺癌流行特征及变化趋势分析[J]. 实用肿瘤学杂志, 2021, 35(3): 200-206. https://www.cnki.com.cn/Article/CJFDTOTAL-SYZL202103002.htmWANG L L, DING G H, CHEN L L, et al. Trends of incidence and mortality of pancreatic cancer in Gansu cancer registration areas, 2009—2015[J]. Journal of Practical Oncology, 2021, 35(3): 200-206. https://www.cnki.com.cn/Article/CJFDTOTAL-SYZL202103002.htm [7] LIN Q J, YANG F, JIN C, et al. Current status and progress of pancreatic cancer in China[J]. World J Gastroenterol, 2015, 21(26): 7988-8003. doi: 10.3748/wjg.v21.i26.7988 [8] MCGUIGAN A, KELLY P, TURKINGTON R C, et al. Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes[J]. World J Gastroenterol, 2018, 24(43): 4846-4861. doi: 10.3748/wjg.v24.i43.4846 [9] MASOUDI S, MOMAYEZ SANAT Z, MAHMUD SALEH A, et al. Menstrual and reproductive factors and risk of pancreatic cancer in women[J]. Middle East J Dig Dis, 2017, 9(3): 146-149. doi: 10.15171/mejdd.2017.65 [10] 韦筱燕, 张家强, 沙莎. 老年人营养风险指数对胰十二指肠切除术患者术后并发症的预测价值[J]. 中华全科医学, 2021, 19(2): 176-178, 231. doi: 10.16766/j.cnki.issn.1674-4152.001760WEI X Y, ZHANG J Q, SHA S. The predictive value of nutritional risk index in elderly patients with postoperative complications after pancreatoduodenectomy[J]. Chinese Journal of General Practice, 2021, 19(2): 176-178, 231. doi: 10.16766/j.cnki.issn.1674-4152.001760 [11] MIDHA S, CHAWLA S, GARG P K, et al. Modifiable and non-modifiable risk factors for pancreatic cancer: a review[J]. Cancer Lett, 2016, 381(1): 269-277. doi: 10.1016/j.canlet.2016.07.022 [12] YU J, BLACKFORD A L, MOLIN M D, et al. Time to progression of pancreatic ductal adenocarcinoma from low-to-high tumour stages[J]. Gut, 2015, 64(11): 1783-1789. doi: 10.1136/gutjnl-2014-308653 [13] PEREIRA S P, OLDFIELD L, NEY A, et al. Early detection of pancreatic cancer[J]. Lancet Gastroenterol Hepatol, 2020, 5(7): 698-710. doi: 10.1016/S2468-1253(19)30416-9 [14] BARTOLI M, BARAT M, DOHAN A, et al. CT and MRI of pancreatic tumors: an update in the era of radiomics[J]. Jpn J Radiol, 2020, 38(12): 1111-1124. doi: 10.1007/s11604-020-01057-6 [15] LOWENFELS A B, MAISONNEUVE P. Epidemiology and prevention of pancreatic cancer[J]. Jpn J Clin Oncol, 2004, 34(5): 238-244. doi: 10.1093/jjco/hyh045 [16] ANSARY-MOGHADDAM A, HUXLEY R, BARZI F, et al. The effect of modifiable risk factors on pancreatic cancer mortality in population of the Asia-Pacific region[J]. Cancer E Pidemiol Biomarkers Prev, 2006, 15(12): 2435-2440. [17] YEO T P. Demographics, epidemiology, and inheritance of pancreatic ductal adenocarcinoma[J]. Semin Oncol, 2015, 42(1): 8-18. [18] 孙惠昕, 陈王洋, 宋冰冰. 黑龙江省2013—2014年度城市癌症筛查分析[J]. 实用肿瘤学杂志, 2015, 29(4): 315-318.SUN H X, CHEN W Y, SONG B B. Analysis of cancer screening of 2013-2014 in Heilongjiang province[J]. Journal of Practical Oncology, 2015, 29(4): 315-318. -
点击查看大图
图(2) / 表(4)
计量
- 文章访问数: 480
- HTML全文浏览量: 59
- PDF下载量: 19
- 被引次数: 0
